AI
By
Can XtalPi & DoveTree’s $6 Billion AI Partnership Transform “Undruggable” Disease Targets in Biopharma – The Dawn of Robotics-Driven R&D at Scale?
Key Highlights: Strategic Overview: Industry’s Largest AI-Pharma CollaborationThis collaboration—one of the biggest in AI-driven drug discovery—combines XtalPi’s robust…
Can Harvard’s FaceAge and Emerging AI Facial Recognition Apps Revolutionize Disease Prediction and Personalized Care in Biopharma and Healthcare?
Key Highlights: AI Facial Recognition as a Medical BiomarkerDeveloped at Harvard Medical School, the FaceAge algorithm analyzes photos…
Could Chai’s $70 Million OpenAI-Backed Funding Propel the Next Leap in AI-Engineered Drug Discovery Success?
Key Highlights Breakthrough Funding and Industry BackingThe Series A round brings Chai Discovery’s total capital to $100 million,…
Is Illinois’ Ban on AI in Mental Healthcare a Turning Point for Human-Centered Therapy Regulation in the U.S.?
Key Highlights Background and Impetus for the BanDriven by incidents where AI chatbots posed risks—including cases suggesting harmful…
Is Lilly’s “TuneLab” the Breakthrough AI Collaboration Model Biotech Startups Have Been Waiting For?
Key Highlights A bold move: Lilly democratizes AI for biotechEli Lilly has launched TuneLab, a novel AI platform…
Could the Medtronic–Abbott Partnership Shift the Future of Diabetes Technology as FDA Clears MiniMed™ 780G for Broader Use?
Key Highlights Expanding Integration Through Abbott PartnershipThe U.S. FDA has cleared Medtronic’s SmartGuard™ algorithm as an interoperable automated…
